Mobile Contingency Management for Marijuana & Tobacco Cessation

Status Completed

Clinical Trial Summary

The purpose of this pilot project is to pilot-test a combined cannabis and smoking cessation treatment. The intervention combines mobile technology with behavioral strategies, counseling, and medications.

Clinical Trial Description

Cannabis is the most widely used illicit drug in the United States with 19.8 million current users. Population based data indicate that almost all cannabis users (90%) have a lifetime history of tobacco smoking and the majority (74%) currently smoke tobacco. While cannabis use alone is associated with significant adverse health effects, tobacco smoking is the number one preventable cause of illness and death in the U.S. This is true even among those using illicit drugs where the tobacco -related mortality rate is twice that of the general population. Among cannabis users, smoking tobacco is associated with increased frequency of marijuana use, increased morbidity, and poorer cannabis cessation outcomes. There is strong evidence for the short -term efficacy for cannabis use disorder (CUD) and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring and effects are short lived. The investigators recently developed a smart -phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. The mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking in the short and long-term. The purpose of this pilot project is to pilot-test a combined cannabis and smoking mCM intervention. The pilot will allow the investigators to examine feasibility of the treatment and of planned recruitment strategies. These project aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both CUD and cigarette smoking. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02869451
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	August 2016
Completion date	May 17, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Recruiting	`NCT02422914` - Benefits of Tobacco Free Cigarette	N/A
Active, not recruiting	`NCT02629679` - Sports, Education and Consumption of Substances in Adolescents	N/A
Completed	`NCT02218281` - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation	N/A
Completed	`NCT02385227` - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes	N/A
Completed	`NCT01199380` - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms	Phase 2
Completed	`NCT01081119` - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth	Phase 2
Completed	`NCT00756704` - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department	N/A
Completed	`NCT00802919` - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors	Phase 4
Completed	`NCT01692353` - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers	N/A
Completed	`NCT00682474` - School Nurse-Delivered Smoking Cessation Intervention	Phase 2/Phase 3
Completed	`NCT05520775` - Semaglutide for Alcohol Use Disorder	Phase 2
Completed	`NCT03743532` - E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services	N/A
Terminated	`NCT03840694` - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior	N/A
Completed	`NCT06032793` - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.	N/A
Terminated	`NCT03326128` - High Dose Bupropion for Smoking Cessation - Pilot Study	Phase 2
Recruiting	`NCT03218670` - Your Health in On Click	N/A
Completed	`NCT02538042` - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Mobile Contingency Management for Marijuana and Tobacco Cessation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms